文献速递儿童青少年精神精神分裂症与精神病性障碍心境障碍

复发性拷贝数变异与多基因评分对精神疾病结局的联合影响

Recurrent Copy Number Variants and Psychiatric Outcomes in the Context of Polygenic Scores.
PubMed 文献 · JAMA Psychiatry · 2026-01-01

该遗传关联研究基于丹麦iPSYCH病例-队列样本,纳入94 276名欧洲裔个体,分析27个复发性拷贝数变异(rCNV)与多基因评分(PGS)对注意缺陷多动障碍(ADHD)、孤独症谱系障碍(ASD)、精神分裂症谱系障碍(SSD)和重性抑郁障碍(MDD)风险的独立与联合效应。结果显示rCNV携带增加ASD、ADHD和SSD风险但不增加MDD风险,各PGS与相应疾病风险正相关;在相似绝对风险水平下,PGS比rCNV识别更多个体(ASD除外),并观察到16p13.11重复与ADHD-PGS对ADHD风险的负交互作用。

要点

  • rCNV携带与ASD、ADHD、SSD风险升高相关,与MDD风险无关。
  • 各疾病对应PGS均与相应疾病风险正相关。
  • 在相似绝对风险下,除ASD外PGS比rCNV识别更多个体。

核心结论

  • rCNV与PGS对精神疾病风险评估具有互补价值。
  • PGS可在中高影响的rCNV携带者中进一步分层风险,且低PGS可能减弱部分rCNV相关风险。

研究设计与样本

  • 遗传关联研究,使用丹麦iPSYCH病例-队列样本,纳入1981-2008年出生、随访至2015年的94 276名无亲缘关系的欧洲裔个体。
  • 暴露为27个常染色体rCNV位点携带状态及精神疾病等结局的PGS,通过新生儿血样微阵列基因分型和已发表关联研究汇总统计量确定。
  • 采用加权生存分析框架估计ADHD、ASD、MDD和SSD的绝对风险,并用广义线性模型评估rCNV与PGS的联合效应。

主要发现

  • rCNV携带与ASD(β=0.33;95%CI,0.27-0.39)、ADHD(β=0.29;95%CI,0.23-0.35)和SSD(β=0.25;95%CI,0.17-0.33)风险增加相关,与MDD无关(β=0.04;95%CI,-0.03至0.11)。
  • 各PGS与相应疾病风险正相关:ADHD-PGS β=0.14(95%CI,0.12-0.16),ASD-PGS β=0.28(95%CI,0.26-0.30),SSD-PGS β=0.28(95%CI,0.26-0.30),MDD-PGS β=0.38(95%CI,0.36-0.40)。
  • 在可比绝对风险水平下,除ASD外,PGS比rCNV携带识别更多个体。
  • 16p13.11重复与ADHD-PGS对ADHD风险存在负交互作用(β=-0.51;95%CI,-0.86至-0.16),且聚合rCNV组及9个最常见rCNV中负交互系数呈趋势(27/39项检验,P二项分布=.01)。

关键数值与推荐

  • rCNV携带增加ASD、ADHD、SSD风险但不增加MDD风险。
  • 各PGS与对应疾病风险正相关,效应量按上述β值及95%CI。
  • 16p13.11重复与ADHD-PGS负交互β=-0.51(95%CI,-0.86至-0.16)。
  • 负rCNV-PGS交互趋势:27/39项检验,P二项分布=.01。

临床怎么用

  • 提示临床风险评估可同时考虑rCNV携带状态与PGS,二者信息互补。
  • 对rCNV携带者,PGS有助于进一步分层风险;低PGS可能减弱部分rCNV相关风险。
  • 在可比绝对风险下,PGS比rCNV识别更多个体(ASD除外),可能影响筛查策略。

局限性

  • 样本限于欧洲裔个体,结果外推需谨慎。
  • 随访至2015年,平均年龄21.9岁,可能未完全捕获晚发疾病。
  • rCNV与PGS交互分析中部分检验未达统计显著,仅呈趋势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although both recurrent copy number variants (rCNVs) and polygenic scores (PGSs) impart risk for psychiatric disorders, it remains unclear how they contribute jointly to this risk. OBJECTIVE: To estimate and compare absolute risk of psychiatric disorders associated with rCNVs and PGSs, independently and jointly. DESIGN, SETTING, AND PARTICIPANTS: This genetic association study applied data from the Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH) case-cohort sample of individuals born in Denmark (1981-2008) and followed up until 2015, including all individuals with a hospital diagnosis of attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), schizophrenia spectrum disorder (SSD), or major depressive disorder (MDD), and a subcohort randomly drawn from the source population. Data were analyzed from September 2023 to May 2025. EXPOSURES: Carrier status was determined at 27 autosomal rCNV loci and PGSs for psychiatric (and other) outcomes from neonatal blood samples genotyped on microarrays and summary statistics from published association studies. MAIN OUTCOMES AND MEASURES: Absolute risks were estimated for ADHD, ASD, MDD, and SSD during follow-up using a weighted survival analysis framework, and joint effects of rCNV carriage and PGSs were assessed by fitting generalized linear models. RESULTS: In 94 276 unrelated European-ancestry individuals (mean [SD] age at follow-up, 21.9 [7.0] years; 50 653 male [53.7%]), rCNV carriage was associated with increased risk of ASD, ADHD, and SSD but not MDD (β = 0.33; 95% CI, 0.27-0.39; β = 0.29; 95% CI, 0.23-0.35; β = 0.25; 95% CI, 0.17-0.33; and β = 0.04; 95% CI, -0.03 to 0.11, respectively); each PGS was positively associated with risk of the corresponding disorder (β = 0.14; 95% CI, 0.12-0.16; β = 0.28; 95% CI, 0.26-0.30; β = 0.28; 95% CI, 0.26-0.30; and β = 0.38; 95% CI, 0.36-0.40, respectively). PGSs identified more individuals than rCNV carriage at comparable levels of absolute risk, except for ASD. A negative interaction was observed between 16p13.11 duplication and ADHD-PGS on ADHD risk (β = -0.51; 95% CI, -0.86 to -0.16), and there was a trend toward negative rCNV-PGS interaction coefficients across aggregated rCNV groups and each of the 9 most common rCNVs (27 of 39 tests, P binomial = .01). CONCLUSIONS AND RELEVANCE: Findings of this genetic association study highlight the complementary value of rCNVs and PGSs for risk assessment in psychiatric disorders, with indications that PGSs can stratify risk among medium- and high-impact rCNV carriers and rCNV-associated risk may, in some instances, be attenuated among individuals with low PGSs.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Vaez M, Montalbano S, Waples R, et al. Recurrent Copy Number Variants and Psychiatric Outcomes in the Context of Polygenic Scores. JAMA Psychiatry. 2026. PMID: 42201728. doi:10.1001/jamapsychiatry.2026.1064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。